{"id":1133,"company":{"country":"US","currency":"USD","exchange":"NYSE MKT LLC","ipo":"1983-12-08","marketCap":123.952392578125,"name":"CEL-SCI Corp","phone":"17035069460.0","outstanding":47.2599983215332,"symbol":"CVM","website":"https://cel-sci.com/","industry":"Biotechnology"},"price":2.425,"year":2023,"month":11,"day":22,"weekday":"Wednesday","title":"The Role of CEL-SCI Corp Stock in a Diversified Investment Portfolio","date":"2023-11-22","url":"/posts/2023/11/22/CVM","content":[{"section":"Introduction","text":"Diversification is an investment strategy that involves spreading investments across different asset classes or sectors to reduce risk. By adding CEL-SCI Corp stock to a diversified portfolio, investors can potentially benefit from the growth prospects of this specific company."},{"section":"Capital Appreciation","text":"Investing in CEL-SCI Corp stock offers the potential for capital appreciation, meaning the value of the investment may increase over time. If the company performs well, the stock price may rise, resulting in potential profits for investors. However, it's important to note that stock prices can also decline, leading to potential losses."},{"section":"Diversification","text":"Including CEL-SCI Corp stock in a diversified investment portfolio can provide diversification benefits. Diversifying investments across various sectors, such as healthcare, reduces the concentration risk of having all investments in a single company or industry. By holding CEL-SCI Corp stock alongside other investments, investors can spread their risk and potentially mitigate the impact of any negative performance within a single stock."},{"section":"Healthcare Exposure","text":"CEL-SCI Corp operates in the healthcare sector, specifically focusing on cancer immunotherapy. Adding this stock to a diversified portfolio provides exposure to the healthcare industry, which can have unique growth opportunities and defensive characteristics. As healthcare demand tends to be more resilient during economic downturns, holding CEL-SCI Corp stock can provide some stability during market fluctuations."},{"section":"Risks and Considerations","text":"Investing in CEL-SCI Corp stock, like any individual stock, carries some risks. The stock price can be affected by factors specific to the company, such as clinical trial results or regulatory decisions. Additionally, market conditions and general economic factors can influence stock prices. It's important for investors to carefully assess their risk tolerance and diversify their investments across multiple stocks and asset classes to manage overall portfolio risk effectively."},{"section":"Conclusion","text":"CEL-SCI Corp stock can serve as a component of a diversified investment portfolio. It offers the potential for capital appreciation, diversification benefits by spreading risk, and exposure to the healthcare sector. However, investors should always consider their own financial goals, risk tolerance, and consult with a financial advisor before making any investment decisions."}],"tags":["CrossOver55","Long","Biotechnology"],"news":[{"category":"company","date":1700514900,"headline":"CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock","id":124005936,"image":"https://media.zenfs.com/en/business-wire.com/827b5d76e2a9d65ac01dadcea669a685","symbol":"CVM","publisher":"Yahoo","summary":"VIENNA, Va., November 20, 2023--CEL-SCI announces closing of $5 million public offering of common stock.","url":"https://finance.yahoo.com/news/cel-sci-announces-closing-5-211500960.html"},{"category":"company","date":1700141400,"headline":"CEL-SCI Announces Pricing of $5 Million Offering of Common Stock","id":123920575,"image":"https://media.zenfs.com/en/business-wire.com/0f1ef450b51d8464f065d5f0f1854c41","symbol":"CVM","publisher":"Yahoo","summary":"VIENNA, Va., November 16, 2023--CEL-SCI announces pricing of $5 million offering of common stock.","url":"https://finance.yahoo.com/news/cel-sci-announces-pricing-5-133000165.html"},{"category":"company","date":1700121180,"headline":"CEL-SCI announces pricing of $5M offering of common stock","id":123929228,"image":"","symbol":"CVM","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215659443"},{"category":"company","date":1700119980,"headline":"CEL-SCI prices $5M offering of common stock at $2.00 per share","id":123929229,"image":"","symbol":"CVM","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215637036"},{"category":"company","date":1699537927,"headline":"12 Best Day Trading Stocks To Buy","id":123757294,"image":"https://media.zenfs.com/en/insidermonkey.com/b88a6cd99e3e146289d108ca0b476020","symbol":"CVM","publisher":"Yahoo","summary":"In this article, we discuss the 12 best day trading stocks to buy. If you want to read about some more day trading stocks, go directly to 5 Best Day Trading Stocks To Buy. Over the past few years, the rise of a new generation of stock traders that like to engage in risky bets, [â€¦]","url":"https://finance.yahoo.com/news/12-best-day-trading-stocks-135207190.html"},{"category":"company","date":1699437960,"headline":"CVM: Target Population Comes Into Relief","id":123723012,"image":"https://s.yimg.com/ny/api/res/1.2/Ex_xdTM9laZKKerPTZ7UHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MTE-/https://media.zenfs.com/en/scr.zacks.com/0077d4546f6fa362f1faf806f17ad0f3","symbol":"CVM","publisher":"Yahoo","summary":"By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Multikine Clinical Data CEL-SCI Corporation (NYSE:CVM) has continued to generate data and analysis related to its IT-MATTERS trial - a Phase III study evaluating Multikine in advanced primary squamous cell carcinoma of the oral cavity and soft palate. Since our previous update a month ago, CEL-SCI has continued to prepare its","url":"https://finance.yahoo.com/news/cvm-target-population-comes-relief-100600736.html"}]}